Search results
Results from the WOW.Com Content Network
Cholesterol synthesis appears to occur mostly at night, [140] so statins with short half-lives are usually taken at night to maximize their effect. Studies have shown greater LDL and total cholesterol reductions in the short-acting simvastatin taken at night rather than the morning, [141] [142] but have shown no difference in the long-acting ...
The activity of each statin is dependent on the binding affinity of the compound for the substrate site and the length of time it binds to the site. [5] Type 2 statins have unique fluorophenyl group that causes additional polar interaction between the enzyme and the statins, which results in a tighter binding to the enzyme.
every night QNS q.n.s. quantity not sufficient q.o.d. every other day (from Latin quaque altera die) (deprecated; use "every other day" instead. See the do-not-use list) QOF: Quality and Outcomes Framework (system for payment of GPs in the UK National Health Service) q.o.h. every other hour q.s.
For premium support please call: 800-290-4726 more ways to reach us
The trial did confirm that, irrespective of dosing time, atorvastatin is very effective at reducing total cholesterol, LDL cholesterol and triglycerides, and increasing HDL cholesterol levels. [41] Hence, atorvastatin should be taken at the same time each day, at a time that is most convenient for the patient, so it does not compromise compliance.
Statin-associated autoimmune myopathy (SAAM), also known as anti-HMGCR myopathy, is a very rare form of muscle damage caused by the immune system in people who take statin medications. [1] However, there are cases of SAAM in patients who have not taken statin medication, and this can be explained by the exposure to natural sources of statin ...
Restrictive cardiomyopathy is when the chambers in your heart become overly stiff over time. This stiffness makes it difficult for your heart to fill with blood. It can be caused by your genetics ...
The Scandinavian Simvastatin Survival Study (also known as the 4S study), was a multicentre, randomized, double-blind, placebo-controlled clinical trial, which provided the initial data that supported the use of the cholesterol-lowering drug, simvastatin, in people with a moderately raised cholesterol and coronary heart disease (CHD); that is people who had previously had a heart attack or angina.